A promising new product generated by the Center for Cell and Gene Therapy, Baylor College of Medicine, involved multiple leukemia antigen–specific T-cells that targeted the tumor-associated antigens PRAME, WT1, and survivin, which are frequently expressed on B-cell and T-cell ALL cells from all 15 donors of patients with ALL who were undergoing allo-HCT. This evidence concerns the gene BIRC5 and acute lymphoblastic leukemia.